444

KRINGLE PHARMA INC

No trades
See on Supercharts
Next report date
Report period
Q2 2024
EPS estimate
Revenue estimate
Market capitalization
‪3.67 B‬JPY
‪−854.15 M‬JPY
‪69.25 M‬JPY
‪4.41 M‬
Beta (1Y)
1.30

About KRINGLE PHARMA INC

CEO
Kiichi Adachi
Headquarters
Osaka
Employees (FY)
13
Founded
2001
ISIN
JP3270790003
FIGI
BBG00YB3CTD5
Kringle Pharma, Inc. engages in the research and development of treatments for regenerative medicine and cancer therapy. It specializes in the research of hepatocyte growth factor (HGF), an intrinsic factor with an organotrophic role in the regeneration and repair of tissues and organs. It also provides research and development of NK4, a multi-targeted angiogenesis inhibitor and a cancer therapeutic. The company was founded by Kunio Matsumoto and Toshikazu Nakamura on December 21, 2001 and is headquartered in Osaka, Japan.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 4884 is 564 JPY — it has decreased by 3.26% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange KRINGLE PHARMA INC stocks are traded under the ticker 4884.
KRINGLE PHARMA INC is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
4884 stock is 5.20% volatile and has beta coefficient of 1.30. Check out the list of the most volatile stocks — is KRINGLE PHARMA INC there?
Yes, you can track KRINGLE PHARMA INC financials in yearly and quarterly reports right on TradingView.
4884 stock has fallen by 0.35% compared to the previous week, the month change is a 3.11% rise, over the last year KRINGLE PHARMA INC has showed a 34.42% decrease.
4884 net income for the last quarter is ‪−169.49 M‬ JPY, while the quarter before that showed ‪−275.52 M‬ JPY of net income which accounts for 38.49% change. Track more KRINGLE PHARMA INC financial stats to get the full picture.
Today KRINGLE PHARMA INC has the market capitalization of ‪3.67 B‬, it has increased by 3.54% over the last week.
No, 4884 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 4884 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KRINGLE PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
4884 reached its all-time high on Dec 28, 2020 with the price of 1780 JPY, and its all-time low was 394 JPY and was reached on Feb 16, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 13.00 employees. See our rating of the largest employees — is KRINGLE PHARMA INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KRINGLE PHARMA INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KRINGLE PHARMA INC stock shows the sell signal. See more of KRINGLE PHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KRINGLE PHARMA INC EBITDA is ‪−899.89 M‬ JPY, and current EBITDA margin is ‪−1.28 K‬%. See more stats in KRINGLE PHARMA INC financial statements.